DRAFT

FOR IMMEDIATE RELEASE

WAVE LIFE SCIENCES, LTD, ANNOUNCES UNPRECEDENTED

GROWTH AND INVESTMENT IN GENETICALLY DEFINED
DISEASES

Wave positioned to unlock potential of nucleic acid therapeutics

90,000 sf facility in Lexington represents investment in

Massachusetts + platform for future growth ANNOUNCES
OFFICIAL OPENING OF NEW LEXINGTON FACILITY

90,000 square foot campus to streamline important work in rare diseases;

represents milestone for Cambridge firm, which has experienced explosive
growth

Families, patient advocacy organizations and state and local join Wave at
new facility

LEXINGTON + CAMBRIDGE [October 16,26 2017] Wave Life Sciences Ltd

(NASDAQ: WVE), a Cambridge-based biotechnology company focused on
delivering transformational therapies for patients with serious, genetically defined
diseases, joined families, patient advocacy organizations and state and local
officials at its new facility today to announce its revolutionary vision and approach
designed to enable patients with a genetic disease to have access to life-
changing treatments in their lifetime. for a ribbon-cutting ceremony to celebrate a
new 90,000 square foot facility in Lexington.

With a scientific team made up of the worlds leading oligonucleotide chemists

focused on rare diseases which have been proven undruggable, the company
is distinguished by a chemistry platform that enables the creation of highly
specific, well-characterized oligonucleotides designed to deliver superior efficacy
and safety across multiple therapeutic modalities. An aggressive plan and
approach devised to advance the treatment, not just the symptoms of the
disease, Wave will undertake 6 proprietary neurology development programs by
the end of 2018.

Waves goal to provide treatments to thousands of patients suffering from

diseases such as ALS, Huntingtons Disease and Duchenne Muscular Dystrophy,
is anchored by its strategy to maintain control of its unique and highly targeted
drug development process. Wave recently moved into a 90,000 sf facility in
Lexington which will enable a fully integrated platform approach, from discovery
through manufacturing, to supply and patient support. The new facility also
represents a commitment by Wave to the Massachusetts. A self described start
up in 2014 with six employees, Wave has grown to over 140 in just a short time,
with a goal to add xx by the end of 2018.

Wave has made a robust commitment to the patient community, early on in the
process as represented by its long-term goal to doing right by its patients,
caregivers, employees and partners. Led by industry veteran Wendy Erly Head
of Patient Engagement, Wendy focuses on xxxx which impact xxx,000 patients in
the rare disease space in the United States.

The facility represents a commitment to Massachusetts and a tremendous step

forward for the fast-growing company, which was founded in 2014 as a start-up
with six employees. The company, which now employs more than 150 in
Cambridge and the new facility in Lexington, is distinguished by a chemistry
platform that enables the creation of highly specific, well-characterized
oligonucleotides designed to deliver superior efficacy and safety across multiple
therapeutic modalities.

Waves efforts are focused on a broad spectrum of rare diseases, potentially

impacting patients suffering from ALS, Duchenne Muscular Dystrophy and
Huntingtons Disease, which makes up approximately XX,0000 patients in the
U.S. Waves goal is to initiate six clinical programs by 2018

QUOTE FROM STATE

\
\
Wave Life Sciences Lexington allows us to maintain control of our unique,
highly-targeted drug development and is essential to realizing promising
treatments that are urgently needed by those suffering with these rare diseases\,
says Paul Bolno, M.D., MBA, President and CEO, Wave Life Sciences. We
anticipate explosive growth in the short term and are now well-positioned to meet
demand.
The firm explored locations around the country for their production facility but
found that the best spot was closest to home. Our search team reviewed many
options but it was soon clear that Massachusetts, which leads the nation in life
science innovation and support for the biotechnology sector, would be best. The
team has already expanded by hundreds, and has plans to hire XX people in the
next year.

Wave was pleased to be joined at the ceremony by the following special guests:
Bob Coughlin, President and CEO Mass Bio (and parent of a child with a rare
disease); Robi Blumenstein, President of The CHDI Foundation, which focuses
on Huntingtons disease; Pat Furlong, President and CEO of PPMD, the largest
nonprofit organization in the United States solely focused on Duchenne muscular
dystrophy; Rich Kennedy, President and Founder of The Angel Fund; Steve
Winthrop, President of the Board for the ALS Association; and Ali and Robyn
Robertson, a family from the UK attending with their children, who have
Duchenne muscular dystrophy

Bob Coughlin Quote: Investment made early/never been done

before/Massachusetts position globally

Quote from Robi or Pat?

Waves ultimate goal is to unleash the promise of nucleic acid therapeutics to

treat numerous diseases which until now have proven undruggable. To date,
nucleic acid therapeutics have been comprised of complex mixtures and multiple
side-effects. Uniquely versatile, Waves technology will be able to maximize
therapeutic effects while minimizing the potential for side effects and safety risks.
(note Im trying to make it simple for all audiences)

The new Wave Life Sciences facility is owned and managed by King Street
Properties.

***
About Wave Life Sciences
Wave Life Sciences is a biotechnology company focused on delivering
transformational therapies for patients with serious, genetically defined diseases.
Our chemistry platform enables the creation of highly specific, well-characterized
oligonucleotides designed to deliver superior efficacy and safety across multiple
therapeutic modalities. Our pipeline is initially focused on neurological disorders
and extends across several other therapeutic areas.
(http://www.wavelifesciences.com/)
Contact:
McDermott Ventures
Carolyn Spicer 617.908.7701

Wave Life Sciences

Jillian Connell 617.949.2981